TAMSOLIN Capsule

ក្រុមហ៊ុនផលិតឱសថ:

 

Getz Pharma(Pvt.) Limited, Pakistan.

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    For the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

    Dosage and administration

    TAMSOLIN capsules 0.4mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. For those patients who fail to respond to the 0.4mg dose after 2-4 weeks of dosing, the dose can be increased to 0.8mg once daily. If TAMSOLIN capsules administration is discontinued or interrupted for several days at either the 0.4mg or 0.8mg dose, therapy should be started again with the 0.4mg once daily dose.

  • ហាមប្រើ

    - With known hypersensitivity to Tamsulosin HCl or any component of the product.

    - With a history of orthostatic hypotension.

    - Taking other alpha-adrenergic blocking agents.

    - With severe hepatic insufficiency.

    Tamsulosin HCl is not indicated for use in:

    - Women.

    - The pediatric population.

  • ផលរំខាន

    Body as whole: Headache, infection, asthenia, back pain, chest pain.

    Nervous System: Dizziness, somnolence, insomnia, decreased libido.

    Respiratory System: Rhinitis, pharyngitis, increased cough, sinusitis.

    Digestive System: Diarrhea, nausea, tooth disorder.

    Urinogenital System: Abnormal ejaculation.

    Special Senses: Blurred vision.

  • អន្តរប្រតិកម្ម

    - The pharmacokinetic interaction between cimetidine and tamsulosin HCl was investigated. The results indicate significant changes in tamsulosin HCl clearance (26% decrease) and AUC (44% increase). Therefore, tamsulosin HCl capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4mg.

    - Caution should be exercised with concomitant administration of warfarin and tamsulosin HCl.

    - Tamsulosin HCl should be used with caution in combination with moderate or strong inhibitors of CYP2D6 (e.g., fluoxetine) or CYP3A4 (e.g., ketoconazole), particularly at doses higher than 0.4mg.

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    Tamsulosin HCl is not indicated for use in women.

  • ការប្រុងប្រយ័ត្នជាពិសេស

    - As with other alpha 1 blockers, reduction in blood pressure can occur in individual cases during treatment with Tamsulosin HCl, as a result of which, very rarely, syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness), the patient should sit or lie down until the symptoms have disappeared.

    - Before therapy with tamsulosin HCl is initiated, the patient should be examined in order to exclude the presence of other conditions which can cause the same symptoms as benign prostatic hyperplasia. Digital rectal examination and, when necessary, determination of prostate specific antigen (PSA) should be performed before treatment and at regular intervals afterwards.

    - Patient with end stage renal disease (creatinine clearance <10mL/min/1.73m2) should be approached with caution as these patients have not been studied.

    - Patient should be advised about the possibility of priapism as a result of treatment with tamsulosin and other similar medications. Patients should be informed that this reaction is extremely rare, but if not brought to immediate medical attention, can lead to permanent erectile dysfunction (impotence).

    - Intra-operative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients taking or who have previously been treated with alpha1 adrenoceptor antagonists.

  • សកម្មភាពឱសថ

    Tamsulosin binds selectively and competitively to postsynaptic α1-adrenoceptors, in particular to subtypes α1A and α1D. It binds about relaxation or prostatic and urethral smooth muscle resulting in an increase in urinary flow rate and a reduction in symptoms of benign prostatic hyperplasia (BPH). It also improves the irritative symptoms in which bladder instability plays an important role.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp